Article Contents ::
- 1 Details About Generic Salt :: Cerivast
- 2 Main Medicine Class:: Antihyperlipidemic,HMG-CoA reductase inhibitor
- 3 (seh-RIHV-ah-stat-in) Baycol Class: Antihyperlipidemic/HMG-CoA reductase inhibitor
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Cerivast
Main Medicine Class:: Antihyperlipidemic,HMG-CoA reductase inhibitor
(seh-RIHV-ah-stat-in)
Baycol
Class: Antihyperlipidemic/HMG-CoA reductase inhibitor
Drugs Class ::
Action Increases rate at which body removes cholesterol from blood and reduces production of cholesterol in body by inhibiting enzyme that catalyzes early rate-limiting step in cholesterol synthesis.
Indications for Drugs ::
Indications Adjunct to diet for the reduction of elevated cholesterol and low-density lipoprotein (LDL) cholesterol levels in patients with primary hypercholesterolemia (types IIa and IIb).
Drug Dose ::
Route/Dosage
ADULTS: PO 0.3 mg in the evening.
Renal impairment (CcrCl £ 60 ml/min): PO 0.2 mg in the evening.
Contraindication ::
Contraindications Active liver disease or unexplained persistent elevations of liver function tests; pregnancy; lactation; concurrent gemfibrozil treatment because of risk of rhabdomyolysis.
Drug Precautions ::
Precautions
Pregnancy: Category X. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Liver dysfunction: Use with caution in patients who consume substantial quantities of alcohol or those with a history of liver disease. Marked, persistent increases in serum transaminases have occurred. Renal function impairment: Use with caution. Lower doses indicated if CrCl £ 60 ml/min. Skeletal muscle effects: Rhabdomyolysis with renal dysfunction secondary to myoglobinuria has occurred.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CNS: Insomnia. GI: Diarrhea; dyspepsia. RESP: Rhinitis; cough; influenza; sinusitis. OTHER: Arthralgia; myalgia; myopathy; rhabdomyolysis; asthenia; edema.
Drug Mode of Action ::
Action Increases rate at which body removes cholesterol from blood and reduces production of cholesterol in body by inhibiting enzyme that catalyzes early rate-limiting step in cholesterol synthesis.
Drug Interactions ::
Interactions
Bile acid sequestrants (eg, cholestyramine): Large decrease in cerivastatin bioavailability. Cyclosporine, gemfibrozil, grapefruit juice, erythromycin, azole antifungals, niacin, verapamil: Increased cerivastatin serum levels; increased risk of myopathy.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note history of liver disease, excessive alcohol ingestion, and renal function. Assess dietary history.
- Ensure that total cholesterol, HDL, and LDL levels have been obtained before beginning therapy and reassess periodically during therapy.
- Assess for the following side effects: nausea, diarrhea, dyspepsia, headache, muscle pain, or weakness.
Drug Storage/Management ::
Administration/Storage
- Administer in the evening for best results. Hepatic cholesterol production is highest during the night.
- May be administered without regard to meals.
- If patient is also taking a bile-acid sequestrant, administer cerivastatin ³ 2 hr after the sequestrant.
- Store at room temperature in tightly closed container, protected from moisture.
Drug Notes ::
Patient/Family Education
- Instruct patient to take dose in the evening without regard to meals.
- If patient is also taking a bile-acid sequestrant, recommend that cerivastatin be taken ³ 2 hr after the sequestrant.
- Explain that full effectiveness of drug may not occur for up to 4 wk after initiation of therapy.
- Teach dietary habits that reduce cholesterol and saturated fats.
- Emphasize importance of follow-up visits to monitor drug effectiveness.
- Instruct patient to report the following symptoms to the health care provider: any unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise; yellowing of skin or eyes.
- Caution female patients of childbearing potential that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use a reliable form of birth control while taking this drug.